Evidence map›Paper›PMID 31545798›Full record

ArticlePloS one2019

Human papillomavirus infection among head and neck squamous cell carcinomas in southern China.

Guoying Ni, Kunsong Huang, Yi Luan, Zaizai Cao, Shu Chen, Bowei Ma, Jianwei Yuan, Xiaolian Wu, Guoqiang Chen, Tianfang Wang and 8 more

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
30citing papers in PubMed, 3 pooled it
4.3field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

30 citing papers in PubMed, 3 syntheses or guidelines pooled it, 45 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Review
  17. Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 5 institutions in 2 countries.

Guoying NiThe First Affiliated Hospital/Clinical Medical School, Guangdong Pharmaceutical University, Guangzhou, Guangdong, China.
Kunsong HuangThe First Affiliated Hospital/Clinical Medical School, Guangdong Pharmaceutical University, Guangzhou, Guangdong, China.
Yi LuanCancer Research Institute, Foshan First People's Hospital, Foshan, Guangdong, China.
Zaizai CaoThe Second Affiliated Hospital, Wenzhou Medical University, Wenzhou, Zhejiang, China.
Shu ChenCancer Research Institute, Foshan First People's Hospital, Foshan, Guangdong, China.
Bowei MaThe First Affiliated Hospital/Clinical Medical School, Guangdong Pharmaceutical University, Guangzhou, Guangdong, China.
Jianwei YuanThe First Affiliated Hospital/Clinical Medical School, Guangdong Pharmaceutical University, Guangzhou, Guangdong, China.
Xiaolian WuCancer Research Institute, Foshan First People's Hospital, Foshan, Guangdong, China.
Guoqiang ChenCancer Research Institute, Foshan First People's Hospital, Foshan, Guangdong, China.
Tianfang WangGenecology Research Centre, University of the Sunshine Coast, Maroochydore DC, QLD, Australia.ORCID 0000-0002-4876-7767
Hejie LiGenecology Research Centre, University of the Sunshine Coast, Maroochydore DC, QLD, Australia.
Shelley WaltonInflammation and Healing Research Cluster, School of Health and Sport Sciences, University of Sunshine Coast, Maroochydore DC, QLD, Australia.
Fang LiuCancer Research Institute, Foshan First People's Hospital, Foshan, Guangdong, China.
Bobei ChenThe Second Affiliated Hospital, Wenzhou Medical University, Wenzhou, Zhejiang, China.
Yuejian WangCancer Research Institute, Foshan First People's Hospital, Foshan, Guangdong, China.
Xuan PanThe First Affiliated Hospital/Clinical Medical School, Guangdong Pharmaceutical University, Guangzhou, Guangdong, China.
Xiaosong LiuThe First Affiliated Hospital/Clinical Medical School, Guangdong Pharmaceutical University, Guangzhou, Guangdong, China.ORCID 0000-0001-9577-7725
Ian H FrazerThe University of Queensland, Faculty of Medicine, Diamantina Institute, Translational Research Institute, Woolloongabba, QLD, Australia.ORCID 0000-0002-8002-4680
First People's Hospital of Foshan · CNUniversity of the Sunshine Coast · AUGuangdong Pharmaceutical University · CNWenzhou Medical University · CNTranslational Research Institute · AU

Funding

CAREER LEADERSHIP AWARDK07AG001003 · NIA · EMORY UNIVERSITY · PI OUSLANDER, JOSEPH G. · 2000 to 2004
$540k
NIA NIH HHS K07 AG001003
6 · The paper itself

Abstract

Human papillomavirus (HPV) related tumours account for a significant proportion of head and neck squamous cell carcinomas (HNSCCs) in developed countries. They respond better to chemo- and radio-therapy, and have a better stage specific prognosis. To establish their prevalence in China, we assessed a series of histology confirmed HNSCCs collected in Zhejiang and Guangdong provinces by PCR for HPV DNA and by immunohistochemistry for p16 protein status. Among 303 HNSCCs, HPV DNA was detected in 26.4%, with HPV16 DNA in 71% of these. Of HNSCC located in the oropharynx, 38.55% (32/83) were HPV+ve. In this series, p16 status was a relatively poor predictor of HPV status as detected by PCR. The stage specific survival time of HPV+ HNSCCs was significantly longer than for HPV- HNSCC. HPV status should be assessed for oropharyngeal cancers in China to assist with appropriate management, and prophylaxis against HPV infection should be considered to reduce the incidence of this disease.

Indexed as

AgedChinaDisease SusceptibilityFemaleGenotypeHumansMaleMiddle AgedNeoplasm StagingPapillomaviridaePapillomavirus InfectionsPrognosisRisk AssessmentRisk FactorsSquamous Cell Carcinoma of Head and NeckSurvival Analysis

Identifiers

PMID31545798
PMCPMC6756512
OpenAlexW2975220332

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.